Vortioxetine - Lundbeck
Alternative Names: Brintellix; LU-AA21004; LuAA 21004; Trintellix; VORTIDIF; vortioxetine-hydrobromideLatest Information Update: 05 Nov 2023
At a glance
- Originator Lundbeck A/S
- Developer Lundbeck A/S; Seoul National University Hospital; Takeda; University of Chicago
- Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Piperazines; Small molecules; Sulfides
- Mechanism of Action 5-HT1A serotonin receptor agonists; Serotonin 1B receptor agonists; Serotonin 1D receptor antagonists; Serotonin 3 receptor antagonists; Serotonin 7 receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Major depressive disorder
- Phase II Anxiety disorders; Binge-eating disorder; Bipolar depression
- Discontinued Attention-deficit hyperactivity disorder; Generalised anxiety disorder
Most Recent Events
- 18 Oct 2022 Efficacy and adverse events data from a phase III MEMORY trial in Major depressive disorder released by Lundbeck
- 17 May 2022 Lundbeck A/S terminates a phase III trial in Major depressive disorder in Bulgaria, Latvia, Spain, Colombia, Mexico, Poland, Russia, Ukraine and USA due to early positive results in other study (PO) (NCT05014919)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in United Kingdom (Sublingual)